Company news
Proqr Therapeutics N.v. (NASDAQ:PRQR) news
Proqr Therapeutics N.v. news releases on 6ix. Latest, Dec 11, 2019: ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal…
Press releases — page 3
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
December 10, 2019
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
November 20, 2019
ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
November 5, 2019
ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10
October 14, 2019
ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
October 14, 2019
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
October 9, 2019
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
September 8, 2019
ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
April 14, 2019